More specifically, the present invention provides a recombinant vector that uses an adeno-associated virus (AAV), a method for manufacturing the recombinant vector, and a method for using the recombinant vector.

The present invention further provides a recombinant vector comprising the polynucleotide encoding the recombinant antibody and a host comprising the vector.

The present disclosure further provides a recombinant vector and a host comprising the vector.

The invention also provides a vaccine comprising the recombinant vector.

Also provided is a recombinant vector containing the DNA, a cell containing the recombinant vector, a pharmaceutical composition containing them, and the use thereof.

A novel thermostable or thermoactive DNA polymerase; DNA coding for the DNA polymerase; a recombinant vector containing the DNA; and a transformant containing the recombinant vector.

  Further disclosed is a recombinant vector carrying a polynucleotide encoding the enzyme.

The present invention also provides for a recombinant nucleic acid or vector that encodes such a PKS, and host cells which also have such a recombinant nucleic acid or vector.

The protein, the DNA encoding the protein, a recombinant vector containing the DNA, and a transformant containing the recombinant vector are useful for screening a substance inhibiting or promoting vascularization.

The said recombinant vector is transformed into Escherichia coli (hereafter E. coli).

Also provided are a recombinant vector for the SCA-related gene, a recombinant cell containing the recombinant vector, and a protein of the SCA-related genetic code.

The present invention relates to a novel 1-cystein peroxiredoxin promoter derived from Oryza sativa L., to a recombinant vector comprising the promoter, and to a transgenic plant using the recombinant vector.

The cDNA-bearing recombinant vector was selected from a human recombinant clone bank constructed in the pUC9 vector.

Also disclosed is a recombinant vector for use in the method.

This protein, DNA encoding the same, a recombinant vector containing this DNA and a transformant having this recombinant vector are usable in screening an NF-kB activation inhibitor or promoter.